Lattanzi, Simona http://orcid.org/0000-0001-8748-0083
Ranzato, Federica
Di Bonaventura, Carlo
Bonanni, Paolo
Gambardella, Antonio
Tartara, Elena
Assenza, Giovanni
Procaccini, Michela
Falsetto, Nathalie
Villano, Valentina
Camattari, Gabriele
Ori, Alessandra
Di Gennaro, Giancarlo
D’Aniello, Alfredo
Catania, Cecilia
Morano, Alessandra
Orlando, Biagio
La Neve, Angela
Francavilla, Teresa
Mazzeo, Francesca Pia
Pauletto, Giada
Belluzzo, Marco
Nilo, Anna Carmen
Peretti, Alessia
Polo, Diana
Lippa, Giulia
Nesta, Marianna
Ricci, Lorenzo
Danieli, Alberto
Osanni, Elisa
Fortunato, Francesco
Magro, Giuseppe
Marino, Laura
Sammarra, Ilaria
Galimberti, Carlo Andrea
Lomonaco, Domenico
Pignatta, Pietro
Collura, Devis
Viglietta, Emanuela
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study
https://doi.org/10.1007/s40120-024-00634-5
Funding for this research was provided by:
Angelini Pharma
Article History
Received: 25 March 2024
Accepted: 15 May 2024
First Online: 8 June 2024
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Simona Lattanzi has received speaker or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Medscape and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals and Rapport Therapeutics. Federica Ranzato has received speaker fees from Angelini Pharma, Eisai, UCB, and LivaNova and has participated in advisory board for Angelini Pharma. Carlo Di Bonaventura has received consulting fees and honoraria from UCB Pharma, Eisai, GW Pharmaceuticals, Bial, Angelini Pharma, Lusofarmaco, and Ecupharma. Paolo Bonanni has received speaker’s or consultancy fees from EISAI, Angelini, Jazz and Livanova and has served on advisory boards for BIAL, Eisai, Proveca outside the submitted work. Antonio Gambardella and Giovanni Assenza declare no conflict of interest. Elena Tartara has received speaker fees from Eisai and advisory board fees from Angelini. Michela Procaccini is an employee of Angelini Pharma, Italy. Nathalie Falsetto is an employee of Angelini Pharma, Italy. Valentina Villano is an employee of Angelini Pharma, Italy. Gabriele Camattari is an employee of Angelini Pharma, Italy. Alessandra Ori is an employee of IQVIA-Medineos. Giancarlo Di Gennaro has received speaker honoraria from EISAI, UCB-Pharma, Livanova, Lusofarmaco, GW Pharmaceuticals. Served on advisory boards for Bial, Arvelle Therapeutics, Angelini Pharma, UCB-Pharma.
: All participants received a comprehensive explanation of the study procedures and goals, consistent with the Declaration of Helsinki (1964 and its later amendments), and voluntarily participated in this study after signing a written informed consent form. The study was approved by the ethics committees of all participating institutions before the start of data collection (first approval of the Coordinating Ethics Committee—Comitato Etico IRCCS Istituto Neurologico Mediterraneo Neuromed—on September 29, 2022; see Supplementary 3—Table S2), and conducted under the guidelines for Good Pharmacoepidemiology Practices (GPP) (Epstein, 2005) and applicable regulatory requirements.